Deadline: 4-Jul-25
The Japanese Headache Society and Pfizer has opened a call for Quality Improvement Grants Program to support activities that improve the medical and scientific expertise of medical professionals and related parties and promote behavioral change toward appropriate diagnosis and treatment, so that migraine patients can receive timely diagnosis and treatment or obtain appropriate information about migraine.
Issues
- The following issues have been pointed out currently in the area of migraine:
- There are quite a few patients who self-treat with over-the-counter analgesics without visiting a medical institution.
- Such patients are at risk of not receiving medical intervention according to the severity of their condition, and of continuing insufficient self-treatment for a long period of time, which may lead to chronic migraine or progression to medication overuse headache (MOH).
- In recent years, the importance of introducing preventive therapy for migraine, which has a high degree of disruption to daily life, has been recognized both domestically and internationally, and migraine treatment is undergoing major changes.
- In order to receive early diagnosis and appropriate treatment for migraine, nonspecialists who may be involved in the initial treatment of patients should acquire the latest knowledge and strengthen cooperation with specialists.
- Early diagnosis is difficult for children and adolescents with migraine, as they may present clinical symptoms different from those of adults. Furthermore, the lack of understanding and knowledge of migraine among family members, school personnel, and industrial physicians in the workplace may lead to missed opportunities for early treatment due to missed opportunities to visit medical institutions.
Funding Information
- Maximum amount per project: 1,200,000 yen
Duration
- Project implementation period: Up to 2 years from December 2025
Eligible Projects
- The following projects are eligible for the grant, which aim to promote behavioral change among medical professionals and improve the quality of medical care:
- Promoting medical cooperation between specialists and non-specialists
- Promoting early diagnosis and appropriate treatment (spreading specialist knowledge
- Promoting disease understanding among children and adolescent patients
- Improving the comprehensive knowledge and understanding of diseases among school doctors, industrial doctors, public health nurses.
Target Audiences
- Healthcare professionals or related parties involved in migraine treatment (school nurses, teachers, public health nurses, pharmacists, etc.)
Eligibility Criteria
- Eligible countries: Japan
- You must belong to one of the following facilities or organizations that have legal status, and apply as an affiliate of that facility or organization.
- Universities,
- university hospitals, regional core hospitals, and other medical educational institutions, Medical academic societies, research groups, etc.
- Medical foundations, NPOs, etc. (corporations engaged in activities related to disease areas, patient groups, patient support groups, etc.)
- Medical Association, Pharmaceutical Association, Dental Association
For more information, visit Pfizer.